Lv11
80 积分 2024-08-27 加入
Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study
8天前
已完结
Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer
8天前
已完结
Response-Adaptive Surgical Timing in neoadjuvant immunotherapy demonstrates enhanced pathologic treatment response in Head and Neck Squamous Cell Carcinoma
8天前
已完结
Neoadjuvant Chemoimmunotherapy Followed by Surgery and Response-Adapted Adjuvant Radiotherapy for Head and Neck Squamous Cell Carcinoma
1个月前
已完结
Neoadjuvant Chemotherapy plus Tislelizumab Followed by Adjuvant Tislelizumab for Locoregionally Advanced Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial
1个月前
已关闭
[Phase Ⅱ clinical trial of PD-1 inhibitor combined with chemotherapy for locally advanced resectable oral squamous cell carcinoma]
1个月前
已完结
[Phase Ⅱ clinical trial of PD-1 inhibitor combined with chemotherapy for locally advanced resectable oral squamous cell carcinoma]
1个月前
已关闭
KEYNOTE-689: A Phase 3 Study of Neoadjuvant and Adjuvant Pembrolizumab Plus Standard of Care (SOC) in Resectable, Locally Advanced (LA) Head and Neck Squamous Cell Carcinoma (HNSCC)
1个月前
已完结
EFFECT-neo: A phase 3 study of pembrolizumab plus chemotherapy versus chemotherapy as neoadjuvant therapy in patients with resectable locally advanced head and neck squamous cell carcinoma
1个月前
已关闭
Immunotherapy with pembrolizumab in surgically resectable head and neck squamous cell carcinoma
3个月前
已关闭
皖公网安备34019202002308
